© Copyright 2012 Chemical Biology Ventures Limited. All Rights Reserved. Registered in England & Wales number 7968150. Registered office: 30 Upper High Street, Thame, Oxfordshire, OX9 3EZ. Address for correspondence: 123 Alexander Close, Abingdon, Oxfordshire, OX14 1XD

CBVlogo4

Optimising pharmaceutical properties

Protein Engineering

Link button

Contact CBV

Tel: +44 (0) 1235 532481

Mob:          07836 554231

Email: [email protected]

Natural proteins often have attractive activities with therapeutic potential but they may not possess ideal pharmaceutical properties. Improvements in stability, selectivity, pharmacokinetics and formulation can be achieved through protein engineering. CBV has experience of developing strategies to improve the properties of proteins to produce an ideal biopharmaceutical product

Example:

Human MIP-1alpha: a chemokine with therapeutic potential

 

Problem:

Protein aggregation causes production issues at scale & increases inflammatory properties of the product

 

Solution:

High-throughput, systematic & site-directed mutagenesis identified key amino acids responsible for protein aggregation. Development of a yeast secretion system for expression of pyrogen-free protein enabled rapid analytical ultracentrifugation assessment of aggregation & preclinical evaluation of the properties of the analogues leading to selection of BB-10010 as a candidate protein.

 

Reference Link:

 

Hunter MG, Bawden L, Brotherton D, Craig S, Cribbes S, Czaplewski LG, Dexter TM, Drummond AH, Heyworth CM, Lord BI, McCourt M, Varley PG, Wood LM, Edwards RM, Lewis PJ.  BB-10010: An active variant of human macrophage inflammatory protein-1 alpha with improved pharmaceutical properties.  Blood 86 (12) 4400-4408, 1995.

 

Czaplewski LG, McKeating J., Craven CJ, Higgins LD, Appay V, Brown A, Dudgeon T, Howard LA, Meyers T, Owen J, Palan SR, Tan P, Wilson G, Woods NR, Heyworth CM, Lord BI, Brotherton D, Christison R, Craig S, Cribbes S, Edwards RM, Evans SJ, Gilbert R, Morgan P, Randle E, Schofield N, Varley PG, Waltho JP, Hunter MG. Identification of amino acid residues critical for aggregation of human CC chemokines MIP-1alpha, MIP-1 beta, and RANTES: characterisation of active disaggregated variants. JBC 274, 16077-16084, 1999.

NMR structure of BB-10010 from Czaplewski et al.

Graphic prepared using PyMol.

MIP-1a